tucatinib
E902879
HER2 inhibitor
antineoplastic agent
approved drug
orally administered drug
protein kinase inhibitor
small-molecule tyrosine kinase inhibitor
Tucatinib is an oral small-molecule tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer, including cases with brain metastases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| tucatinib canonical | 4 |
How this entity was disambiguated
This entity first appeared as the object of triple T11074262 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: tucatinib Context triple: [HER2 receptor, targetOfDrug, tucatinib]
-
A.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
B.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
-
C.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
D.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
E.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: tucatinib Target entity description: Tucatinib is an oral small-molecule tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer, including cases with brain metastases.
-
A.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
B.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
-
C.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
D.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
E.
Lynparza
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
HER2 inhibitor
ⓘ
antineoplastic agent ⓘ approved drug ⓘ orally administered drug ⓘ protein kinase inhibitor ⓘ small-molecule tyrosine kinase inhibitor ⓘ |
| crosses | blood–brain barrier ⓘ |
| hasApprovalYear | 2020 ⓘ |
| hasATCCode | L01EH05 ⓘ |
| hasClinicalTrial | HER2CLIMB ⓘ |
| hasCommonAdverseEffect |
diarrhea
ⓘ
elevated liver enzymes ⓘ fatigue ⓘ nausea ⓘ palmar-plantar erythrodysesthesia ⓘ vomiting ⓘ |
| hasDeveloper |
Seagen Inc.
ⓘ
linked to:
Seattle Genetics
|
| hasDosageForm | oral tablet ⓘ |
| hasEffect |
inhibits tumor cell proliferation in HER2-overexpressing cells
ⓘ
reduces phosphorylation of HER2 ⓘ reduces phosphorylation of downstream signaling proteins ⓘ |
| hasEffectInTrial |
improved overall survival in HER2-positive metastatic breast cancer
ⓘ
improved progression-free survival in HER2-positive metastatic breast cancer ⓘ |
| hasIndication |
HER2-positive breast cancer
ⓘ
HER2-positive breast cancer with brain metastases ⓘ HER2-positive metastatic colorectal cancer ⓘ metastatic HER2-positive breast cancer ⓘ unresectable HER2-positive breast cancer ⓘ |
| hasIndicationDetail | patients who have received prior anti-HER2-based regimens in the metastatic setting ⓘ |
| hasMechanismOfAction |
inhibition of HER2-driven cell signaling
ⓘ
selective inhibition of HER2 tyrosine kinase ⓘ |
| hasMolecularFormula | C26H24N8O2 ⓘ |
| hasMolecularWeight | 480.52 g/mol ⓘ |
| hasPregnancyCategory | embryo-fetal toxicity risk ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasRouteOfElimination | hepatic ⓘ |
| hasSeriousAdverseEffect |
hepatotoxicity
ⓘ
severe diarrhea ⓘ |
| hasTradeName | Tukysa ⓘ |
| hasUsualAdultDose | 300 mg twice daily ⓘ |
| isApprovedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| isInhibitorOf |
CYP3A4
ⓘ
P-glycoprotein ⓘ |
| isMetabolizedBy |
CYP2C8
ⓘ
CYP3A4 ⓘ |
| isUsedInCombinationWith |
capecitabine
ⓘ
trastuzumab ⓘ
linked to:
Herceptin
|
| targets |
ERBB2
ⓘ
HER2 ⓘ
linked to:
ERBB2
|
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: tucatinib Description of subject: Tucatinib is an oral small-molecule tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer, including cases with brain metastases.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.